XI’AN, China, July 3 /Xinhua-PRNewswire-FirstCall/ -- Huifeng
Bio-Pharmaceutical Technology, Inc. (OTC Bulletin Board: HFGB), a leading developer and producer of plant extracts and pharmaceutical raw materials for use in pharmaceutical, nutraceutical and food production in China, announced today that its company information will be made available via Standard & Poor’s Market Access Program, an information distribution service that enables subscribing publicly traded companies to have their company information disseminated to users of Standard & Poor’s Advisor Insight. The company information to be made available through this program includes share price, volume, dividends, shares outstanding, company financial position, and earnings. Standard & Poor’s Advisor Insight is an Internet-based research engine used by more than 100,000 investment advisors. A public version of the site is available at http://www.advisorinsight.com .
In addition, information about companies in Standard & Poor’s Market Access Program will be available via S&P’s Stock Guide database, which is distributed electronically to virtually all major quote vendors. As part of the program, a full description of Huifeng Bio-Pharmaceutical Technology, Inc. will also be published in the Daily News section of Standard Corporation Records, a recognized securities manual for secondary trading in approximately 38 states under their Blue Sky Laws.
About Huifeng Bio-Pharmaceutical Technology, Inc.
Huifeng Bio-Pharmaceutical Technology, Inc., located in Xi’an, People’s Republic of China, develops and produces plant extracts and pharmaceutical raw materials for use in pharmaceutical, nutraceutical and food production. It is the leading Chinese producer of rutin and related plant-derived chemicals in a class called flavonoids, with medicinal and other beneficial properties. Founded in 2002, Huifeng uses proprietary patented processes to extract rutin more efficiently than traditional extraction techniques. The Company is diversifying its product lines through internal development, acquisition and cooperation with scientific research organizations. Additional information about Huifeng can be found from their website, http://www.hfgb.cn .
Company information distributed through the Market Access Program is based upon information that Standard & Poor’s considers to be reliable, but neither Standard & Poor’s nor its affiliates warrant its completeness or accuracy, and it should not be relied upon as such. This material is not intended as an offer or solicitation for the purchase or sale of any security or other financial instrument.
For more information, please contact:
Huifeng Bio-Pharmaceutical Technology, Inc.
Daniel Carlson
Primary Capital LLC.
Tel: +1-415-460-1165
Email: DCarlson@PrimaryLLC.com
Standard & Poor’s Customer Contact:
Richard Albanese
Tel: +1-212-438-3647
Email: richard_albanese@sandp.com
Standard and Poor’s Media Relations Contact:
Michael Privitera
Tel: +1-212-438-6679
Email: michael_privitera@sandp.com
